NOS2 and -nitrosothiol Signaling Induces DNA Hypomethylation and LINE-1 Retrotransposon Expression

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2022 May 18

PMID 35584114

Authors

Christopher H Switzer

Hyun-Ju Cho

Thomas R Eykyn

Paul Lavender

Philip Eaton

Affiliations

Soon will be listed here.

Abstract

Inducible nitric oxide synthase (NOS2) produces high local concentrations of nitric oxide (NO), and its expression is associated with inflammation, cellular stress signals, and cellular transformation. Additionally, NOS2 expression results in aggressive cancer cell phenotypes and is correlated with poor outcomes in patients with breast cancer. DNA hypomethylation, especially of noncoding repeat elements, is an early event in carcinogenesis and is a common feature of cancer cells. In addition to altered gene expression, DNA hypomethylation results in genomic instability via retrotransposon activation. Here, we show that NOS2 expression and associated NO signaling results in substantial DNA hypomethylation in human cell lines by inducing the degradation of DNA (cytosine-5)–methyltransferase 1 (DNMT1) protein. Similarly, NOS2 expression levels were correlated with decreased DNA methylation in human breast tumors. NOS2 expression and NO signaling also resulted in long interspersed noncoding element 1 (LINE-1) retrotransposon hypomethylation, expression, and DNA damage. DNMT1 degradation was mediated by an NO/p38-MAPK/lysine acetyltransferase 5–dependent mechanism. Furthermore, we show that this mechanism is required for NO-mediated epithelial transformation. Therefore, we conclude that NOS2 and NO signaling results in DNA damage and malignant cellular transformation via an epigenetic mechanism.

Citing Articles

Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome.

Palczewski M, Kuschman H, Hoffman B, Kathiresan V, Yang H, Glynn S Nat Commun. 2025; 16(1):1732.

PMID: 39966373 PMC: 11836389. DOI: 10.1038/s41467-025-56928-1.

The Advances in the Development of Epigenetic Modifications Therapeutic Drugs Delivery Systems.

Li T, Chen Y, Li S Int J Nanomedicine. 2024; 19:10623-10637.

PMID: 39445155 PMC: 11498046. DOI: 10.2147/IJN.S480095.

Inflammaging and Brain Aging.

Jurcau M, Jurcau A, Cristian A, Hogea V, Diaconu R, Nunkoo V Int J Mol Sci. 2024; 25(19).

PMID: 39408862 PMC: 11476611. DOI: 10.3390/ijms251910535.

Deconvoluting nitric oxide-protein interactions with spatially resolved multiplex imaging.

Li Y, Pan K, Gao Y, Li J, Zang Y, Li X Chem Sci. 2024; 15(17):6562-6571.

PMID: 38699271 PMC: 11062118. DOI: 10.1039/d4sc00767k.

Nitric oxide inhibits ten-eleven translocation DNA demethylases to regulate 5mC and 5hmC across the genome.

Thomas D, Palczewski M, Kuschman H, Hoffman B, Yang H, Glynn S Res Sq. 2024; .

PMID: 38645113 PMC: 11030528. DOI: 10.21203/rs.3.rs-4131804/v1.

References

Burr S, Caldwell A, Chong M, Beretta M, Metcalf S, Hancock M . Oxygen gradients can determine epigenetic asymmetry and cellular differentiation via differential regulation of Tet activity in embryonic stem cells. Nucleic Acids Res. 2017; 46(3):1210-1226. PMC: 5814828. DOI: 10.1093/nar/gkx1197. View

Gasior S, Wakeman T, Xu B, Deininger P . The human LINE-1 retrotransposon creates DNA double-strand breaks. J Mol Biol. 2006; 357(5):1383-93. PMC: 4136747. DOI: 10.1016/j.jmb.2006.01.089. View

Akaike T, Maeda H . Nitric oxide and virus infection. Immunology. 2000; 101(3):300-8. PMC: 2327086. DOI: 10.1046/j.1365-2567.2000.00142.x. View

Wang L, Tang W, Yang S, He P, Wang J, Gaedcke J . NO /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. Int J Cancer. 2019; 146(11):3160-3169. PMC: 8189162. DOI: 10.1002/ijc.32733. View

Kemp J, Longworth M . Crossing the LINE Toward Genomic Instability: LINE-1 Retrotransposition in Cancer. Front Chem. 2016; 3:68. PMC: 4679865. DOI: 10.3389/fchem.2015.00068. View

Hermann A, Goyal R, Jeltsch A . The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites. J Biol Chem. 2004; 279(46):48350-9. DOI: 10.1074/jbc.M403427200. View

Glynn S, Boersma B, Dorsey T, Yi M, Yfantis H, Ridnour L . Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest. 2010; 120(11):3843-54. PMC: 2964971. DOI: 10.1172/JCI42059. View

van Veldhoven K, Polidoro S, Baglietto L, Severi G, Sacerdote C, Panico S . Epigenome-wide association study reveals decreased average methylation levels years before breast cancer diagnosis. Clin Epigenetics. 2015; 7:67. PMC: 4524428. DOI: 10.1186/s13148-015-0104-2. View

OConnor K, Das A, Winterbourn C, Hampton M . Inhibition of DNA methylation in proliferating human lymphoma cells by immune cell oxidants. J Biol Chem. 2020; 295(23):7839-7848. PMC: 7278342. DOI: 10.1074/jbc.RA120.013092. View

10.

Aranda E, Lopez-Pedrera C, de la Haba-Rodriguez J, Rodriguez-Ariza A . Nitric oxide and cancer: the emerging role of S-nitrosylation. Curr Mol Med. 2011; 12(1):50-67. DOI: 10.2174/156652412798376099. View

11.

Sha Y, Marshall H . S-nitrosylation in the regulation of gene transcription. Biochim Biophys Acta. 2011; 1820(6):701-11. PMC: 4403761. DOI: 10.1016/j.bbagen.2011.05.008. View

12.

Switzer C, Glynn S, Cheng R, Ridnour L, Green J, Ambs S . S-nitrosylation of EGFR and Src activates an oncogenic signaling network in human basal-like breast cancer. Mol Cancer Res. 2012; 10(9):1203-15. PMC: 3463231. DOI: 10.1158/1541-7786.MCR-12-0124. View

13.

Batra R, Lifshitz A, Tufegdzic Vidakovic A, Chin S, Sati-Batra A, Sammut S . DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. Nat Commun. 2021; 12(1):5406. PMC: 8437946. DOI: 10.1038/s41467-021-25661-w. View

14.

Hickok J, Vasudevan D, Antholine W, Thomas D . Nitric oxide modifies global histone methylation by inhibiting Jumonji C domain-containing demethylases. J Biol Chem. 2013; 288(22):16004-15. PMC: 3668755. DOI: 10.1074/jbc.M112.432294. View

15.

Thomsen L, Miles D, Happerfield L, Bobrow L, Knowles R, Moncada S . Nitric oxide synthase activity in human breast cancer. Br J Cancer. 1995; 72(1):41-4. PMC: 2034139. DOI: 10.1038/bjc.1995.274. View

16.

Kazazian Jr H, Goodier J . LINE drive. retrotransposition and genome instability. Cell. 2002; 110(3):277-80. DOI: 10.1016/s0092-8674(02)00868-1. View

17.

Hill D, Jamin Y, Orton M, Tardif N, Parkes H, Robinson S . ¹H NMR and hyperpolarized ¹³C NMR assays of pyruvate-lactate: a comparative study. NMR Biomed. 2013; 26(10):1321-1325. PMC: 4298370. DOI: 10.1002/nbm.2957. View

18.

Chen R, Pettersson U, Beard C, Jaenisch R . DNA hypomethylation leads to elevated mutation rates. Nature. 1998; 395(6697):89-93. DOI: 10.1038/25779. View

19.

Eyler C, Wu Q, Yan K, MacSwords J, Chandler-Militello D, Misuraca K . Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 2011; 146(1):53-66. PMC: 3144745. DOI: 10.1016/j.cell.2011.06.006. View

20.

Kazazian Jr H, Moran J . Mobile DNA in Health and Disease. N Engl J Med. 2017; 377(4):361-370. PMC: 5980640. DOI: 10.1056/NEJMra1510092. View